All Outputs (2)

A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine (2013)
Journal Article
Walsby, E., Pratt, G., Shao, H., Abbas, A. Y., Fischer, P., Bradshaw, T. D., …Pepper, C. (2013). A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine. Oncotarget, 5, 375-385

Cdk9 is a key elongation factor for RNA transcription and functions by phosphorylating the C-terminal domain of RNA polymerase II. Here we present direct evidence that cdk9 is important for cancer cell survival and describe the characterization of th... Read More about A novel Cdk9 inhibitor preferentially targets tumor cells and synergizes with fludarabine.

Apoferritin-encapsulated PbS quantum dots significantly inhibit growth of colorectal carcinoma cells (2013)
Journal Article
Bradshaw, T. D., Junor, M., Patanè, A., Clarke, P., Thomas, N. R., Li, M., …Turyanska, L. (2013). Apoferritin-encapsulated PbS quantum dots significantly inhibit growth of colorectal carcinoma cells. Journal of Materials Chemistry B, 45, 6254-6260. https://doi.org/10.1039/c3tb21197e

Colorectal carcinoma (CRC) is the 3rd most common cancer worldwide, thus development of novel therapeutic strategies is imperative. Herein potent, selective dose-dependent antitumor activity of horse spleen apoferritin encapsulated PbS quantum dots (... Read More about Apoferritin-encapsulated PbS quantum dots significantly inhibit growth of colorectal carcinoma cells.